NVOX

Defiance Daily Target 2X Long NVO ETF

Defiance · $36.5m in assets, October 8, 2026

An actively managed ETF: aims for twice the daily return of NVO shares, using swaps and listed options. Because it resets daily, longer-term returns can differ a lot from twice NVO's.

NVOX, the Defiance Daily Target 2X Long NVO ETF, is a $37 million ETF whose main story is the biology trade. Over the past year it returned −71.2%, against +16.8% for broad US ETFs. Figures to October 2, 2026; past performance, not a recommendation.

NVOX · the ETFFRI OCT 2Market price total return
−79.2% a yearTotal return since launch, December 2024
−71.2%Last 12 months
−58.4%Year to date
99.2%Volatility since launch

The narrative it carries

This is its only narrative.

The biology trade →

Health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.

The biology trade · the narrative this week
41.2QUIET level, 20 of 22
last four weeks
92ETFs carry it
73.3%held by the top five
XLVlargest holder, 36.3%
$119 bncapital, 10th of 22

The band is where this narrative’s level sits among the 22 this week. QUIET means less talked about, not falling.

Who owns the capital
XLV 36.3%VHT 15.3%IBB 9.4%XBI 8.7%IXJ 3.6%87 other ETFs 26.7%73.3%top five
#ETFSHAREASSETS1 YEARCOST
1XLV36.3%$43.39bn+18.0%0.08%
2VHT15.3%$18.31bn+18.9%0.09%
3IBB9.4%$11.20bn+37.5%0.44%
4XBI8.7%$10.36bn+51.2%0.35%
5IXJ3.6%$4.32bn+11.8%–
87 other ETFs26.7%
NVOX carries this narrative but holds no Share of Narrative, because only unlevered long exposure counts.

Share is each ETF’s slice of the capital carrying this narrative. 1 year is market price total return; cost is the expense ratio. See all 92 ETFs on the narrative page →

FRI OCT 2MARKET PRICE TOTAL RETURN

1M3MYTD1Y3Y*5Y*
NVOX−38.2%−48.7%−58.4%−71.2%––
The biology tradeits narrative−3.5%+2.1%+13.7%+24.2%+15.2%+6.7%
The marketbroad US ETFs+0.8%+2.6%+14.6%+16.8%+22.9%+12.9%

1M, 3M, 1Y, 3Y, 5Y: one month to five years. YTD: year to date. * A year, annualised. A dash means the ETF has not traded for the whole period. Since it started trading on December 3, 2024: −79.2% a year.

$10,000 invested December 31, 2024

NVOX $971The biology trade $13,591The market $13,394
$0$10,000$20,000Dec 2024Jun 2025Dec 2025Jun 2026$0$10,000$20,000Dec 2024Dec 2025

Year by year

NVOXThe biology tradeThe market
-80%-60%-40%-20%0%20%NVOX 2025: -76.7%Narrative 2025: +19.5%The market 2025: +16.8%2025NVOX YTD: -58.4%Narrative YTD: +13.7%The market YTD: +14.6%YTD-80%-60%-40%-20%0%20%NVOX 2025: -76.7%Narrative 2025: +19.5%The market 2025: +16.8%2025NVOX YTD: -58.4%Narrative YTD: +13.7%The market YTD: +14.6%YTD

Total return in each calendar year; this year is year to date. A year appears only if NVOX traded for all of it.

Total return on the market price, with each distribution reinvested on its ex-date. Not the NAV return the issuer publishes; the two differ when the ETF trades above or below the value of its holdings. The narrative is the asset-weighted return of the unlevered ETFs that carry it. The market is the asset-weighted return of broad US index ETFs. Past performance is no guarantee of future results.

Common questions

What story is NVOX selling?

NVOX’s main story is the biology trade, which covers health care from drugmakers and insurers to genomics: the science that gets approved, and who pays for it.

Which ETFs compete with NVOX?

The ETFs whose weekly returns move most like NVOX’s over the past 3 years are NVOH (0.99), EDEN (0.81) and OZEM (0.70).

How has NVOX performed against its story?

Over the past year NVOX returned −71.2%, the ETFs carrying the biology trade +24.2% and broad US ETFs +16.8%, to October 2, 2026. Its weekly returns have a correlation of 0.46 with the story. Past performance only.

Run an ETF in the biology trade? StoryVector shows issuers where their ETFs stand against the closest rivals, every week.

Request a pilot
Narrative figures are from the weekly board. Performance is market price total return as of October 2, 2026. Assets are StoryVector’s weekly figure. Classification and measurement. Not investment advice. How the measurement works →